Patent ID: 11865164
Assignee: G+FLAS LIFE SCIENCES
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a cancer in a subject in need thereof comprising administering an effective amount of a composition to the subject,
wherein the composition comprises a vector containing (a) an isolated polynucleotide complementarily binding to a nucleic acid specifically present in cancer cells; (b) an isolated polynucleotide encoding an endonuclease; and (c) an isolated polynucleotide encoding an exonuclease, and
wherein the exonuclease is selected from the group consisting of RecBCD, RecE, RecJ, T5, Exo I, Exo III, Exo VII, Lexo, TREX2, Exoribonuclease T, TREXI, Mungbean exonuclease, Lambda, and a combination thereof,
wherein the nucleic acid specifically present in cancer cells is selected from the genes of which copy number variation (CNV) is at least 4,
wherein the endonuclease is a clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein selected from a group consisting of Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, Cas10, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, Cas13a, Cas13b, Cas13c, Cas13d, Cas14, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, CsMT2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4, and
wherein the endonuclease and the exonuclease are of a fusion protein.